DexCom, Inc.
Price
Overview
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
Leadership
As Chief Executive Officer of DexCom, Inc., Jacob Steven Leach leads a global leader in continuous glucose monitoring (CGM) technology. DexCom designs, develops, and markets innovative systems that help people manage their diabetes by providing real-time glucose readings directly to a user's smart device. Their integrated approach aims to simplify diabetes management, reduce the burden of daily routines, and empower individuals with actionable data to make informed health decisions. The company's products are crucial for both type 1 and type 2 diabetes patients seeking more effective ways to track and control their glucose levels, contributing significantly to improved quality of life and potentially reducing long-term health complications associated with diabetes. Leach brings a wealth of experience in the medical technology sector to his role at DexCom. Prior to becoming CEO, he held various senior leadership positions within the company, contributing to its growth and strategic direction. His career has been dedicated to advancing healthcare solutions, with a focus on technologies that improve patient outcomes and address significant unmet medical needs. Before joining DexCom, he gained extensive experience in the medical device industry, holding leadership roles where he was instrumental in product development, commercialization strategies, and building high-performing teams. This deep understanding of the healthcare landscape and the intricacies of the medical device market has been fundamental to his success. Under Leach's leadership, DexCom has continued to emphasize innovation, expanding its product capabilities and global reach. A key strategic priority has been the ongoing development and integration of advanced sensing technologies and connected software solutions, aiming to create a more seamless and comprehensive diabetes management ecosystem. He has fostered a culture focused on patient-centricity, driving the company to address the evolving needs of individuals with diabetes. Today, DexCom stands as a prominent force in the rapidly growing CGM market, recognized for its technological advancements, strong market position, and commitment to improving the lives of millions worldwide.
History & business model
This section is waiting to be written.
InvestWiki is community-edited. Contribute a plain-English history of DexCom, Inc., its business model, key products, and controversies.